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Aims: Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with type
2 diabetes (T2D) and moderate renal impairment (estimated glomerular filtration rate [eGFR],
45–59 mL/min/1.73 m2; chronic kidney disease [CKD] stage 3A).
Materials and methods: In this double-blind, parallel group, Phase 3 study (NCT02413398,
clinicaltrials.gov) patients with inadequately controlled T2D (HbA1c 7.0%-11.0%) were random-
ized (1:1) to dapagliflozin 10 mg once daily (N = 160) or matching placebo (N = 161) for
24 weeks. Randomization was stratified by pre-enrolment glucose-lowering therapy. The
primary endpoint was change from baseline in HbA1c at Week 24.
Results: At Week 24, compared with placebo, dapagliflozin significantly decreased HbA1c
(difference [95% CI], −0.34% [−0.53, −0.15]; P < 0.001), body weight (difference [95% CI],
−1.25 kg [−1.90, −0.59]; P < 0.001), fasting plasma glucose (difference [95% CI], −0.9 mmol/L
[−1.5, −0.4]; P = 0.001) and systolic blood pressure (difference [95% CI], −3.1 mm Hg [−6.3,
0.0]; P < 0.05). Decreases from baseline in eGFR were greater with dapagliflozin than placebo at
Week 24 (−2.49 mL/min/1.73 m2 [−4.96, −0.02]), however, eGFR returned to baseline levels at
Week 27 (3 weeks post-treatment) (0.61 mL/min/1.73 m2 [−1.59, 2.81]). No increase in adverse
events (AEs; 41.9% vs 47.8%) or serious AEs (5.6% vs 8.7%) were reported with dapagliflozin
versus placebo. No AEs of bone fractures, amputations or DKA were reported.
Conclusions: The findings of this study (NCT02413398, clinicaltrials.gov) support the positive
benefit/risk profile of dapagliflozin for the treatment of patients with T2D and CKD 3A.
1 | INTRODUCTION
Diabetes is a risk factor for chronic kidney disease (CKD).1 The global
rise in diabetes has led to an increase in the incidence of CKD, with
over 35% of patients with diabetes aged ≥20 years having a diagnosis
*Listed in Appendix S1.
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of CKD.2 Optimal glycaemic control in patients with diabetes and
CKD is crucial, to reduce the risk of further complications, as well as
the progression rate of CKD.3 However, glucose-lowering treatment
options in this population are limited, and several drugs have label
restrictions concerning CKD.3–5 Furthermore, patients with CKD are
at greater risk of developing severe hypoglycaemia, and medications
that carry a high risk of hypoglycaemia3–6 may be less appropriate for
this population. New treatment options for patients with diabetes and
CKD are therefore needed to optimize outcomes.
Dapagliflozin is a selective inhibitor of sodium glucose co-transporter
2 (SGLT2) that causes glycosuria and lowers blood glucose levels regard-
less of insulin sensitivity and β-cell secretory function.7,8 Dapagliflozin is
associated with reductions in blood pressure and body weight,9,10 and
carries a low intrinsic risk of hypoglycaemia.11 SGLT2 inhibitors have also
demonstrated cardiovascular (CV) and renal benefits.12–16
Because dapagliflozin's mode of action is dependent on blood glu-
cose levels and glomerular filtration rate (GFR),17 its glucose-lowering
effects are attenuated in patients with moderate renal impairment18
(estimated GFR [eGFR], 30–59 mL/min/1.73 m2; chronic kidney dis-
ease [CKD] stage 3) as the result of a reduced filtered glucose load.
Kohan et al. reported no significant improvements in glycaemic control
with dapagliflozin vs placebo in this population (mean change from
baseline in HbA1c [SE], −0.41% [0.17], −0.44% [0.17] and −0.32%
[0.17] with dapagliflozin 5 mg, dapagliflozin 10 mg and placebo, respec-
tively).18 However, beneficial effects on body weight (mean change
from baseline at Week 24 [SD], −1.34 [0.43] kg and −1.72 [0.44] kg vs
0.68 [0.45] kg for dapagliflozin 5 and 10 mg vs placebo, respectively)
and systolic blood pressure (SBP) (mean change from baseline at Week
104 [SD], −0.25 [18.30] mm Hg, −2.51 [16.33] vs 4.14 [14.07], respec-
tively) were observed with dapagliflozin.18 Of note, there was a reduc-
tion in HbA1c with dapagliflozin relative to placebo in patients with
CKD stage 3A (eGFR, 45–59 mL/min/1.73 m2), but not in those with
CKD stage 3B (eGFR, 30–44 mL/min/1.73 m2).
Further understanding regarding the use of dapagliflozin in the
management of patients with T2D and CKD is thus required. Here we
assess the efficacy and safety of dapagliflozin 10 mg in patients with
T2D and CKD stage 3A (eGFR, 45–59 mL/min/1.73 m2).
2 | MATERIALS AND METHODS
2.1 | Study design
This was a randomized, double-blind, 2-arm, parallel group, placebo-con-
trolled, multinational, Phase 3 study to evaluate the efficacy and safety of
dapagliflozin in patients with T2D and CKD stage 3A (eGFR, 45–59 mL/
min/1.73 m2; based on the modification of diet in renal disease [MDRD]
formula).19 The study was conducted at 88 centres in the USA, Canada,
Bulgaria, the Czech Republic, Italy, Poland, Spain and Sweden.
Patients were randomized (1:1) to 24 weeks of treatment with
dapagliflozin 10 mg or matching placebo. The study consisted of a
2-week screening period, a 4-week single-blind placebo lead-in period,
a 24-week double-blind treatment period and a 3-week post-
treatment follow-up period. It was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice Guidelines as
defined by the International Conference on Harmonization. The study
was approved by the institutional review boards and independent
ethics committees of all participating centres. All participants provided
written informed consent prior to inclusion in the study. This study is
registered at ClinicalTrials.gov (NCT02413398) and the study protocol
is available online: http://astrazenecagrouptrials.pharmacm.com.
2.2 | Participants
The study included male and female patients (≥18 to <75 years) who have
had T2D for >12 months, inadequate glycaemic control (HbA1c ≥7.0%
and ≤11.0% at screening) and a body mass index (BMI) of 18–45 kg/m2
at Visit 1, who are undergoing a stable glucose-lowering treatment regi-
men (stable diet and exercise alone or in combination with any approved
oral glucose-lowering medication, except SGLT2-inhibitors, and/or long/
intermediate-acting insulin or mixed insulin), and who had CKD 3A (eGFR,
40–65 mL/min/1.73 m2 at Visit 1 to enter the lead-in period and eGFR,
45–59 mL/min/1.73 m2 at Visits 1, 2 or 3 to be randomized).
Patients were excluded if they had a history of severe uncontrolled
hypertension, certain CV/vascular diseases within 3 months prior to
enrolment (myocardial infarction, cardiac surgery or revascularization,
unstable angina, unstable heart failure, heart failure Class IV according
to the New York Heart Association [NYHA], transient ischaemic attack
or significant cerebrovascular disease, unstable or previously undiag-
nosed arrhythmia), or certain renal diseases (rapid worsening of renal
function from Visit 1 to Visit 3, intercurrent kidney disease other than
diabetic nephropathy, renal transplant, dialysis or ultrafiltration). The
use of metformin was restricted to doses for moderate renal impair-
ment (eGFR, 30–59 mL/min/1.73 m2) according to local guidelines or
the investigator's judgement. Patients were excluded if they had
received treatment with an SGLT2 inhibitor, a glucagon-like peptide
1 (GLP-1) receptor agonist or a rapid/short-acting insulin at screening.
In addition, patients who had a serum potassium level of >5.5 mmol/L,
a serum calcium level of <1.99 mmol/L or > ULN, or a haemoglobin
level of ≤90 g/L were also excluded. The full list of inclusion/exclusion
criteria can be found in Table S1.
2.3 | Interventions
Patients with T2D were randomized to dapagliflozin 10 mg once daily
or matching placebo, taken orally in the morning, in addition to their
usual care. Randomization was stratified by pre-enrolment glucose-
lowering therapy (long/intermediate-acting and mixed insulin regimen,
metformin, sulphonylurea, thiazolidinedione or other regimen). Oral
glucose-lowering drugs (apart from SGLT2 inhibitors), insulin (apart
from rapid/short-acting insulins), antihypertensive drugs, lipid-lowering
drugs and anti-platelet drugs were permitted as long as the dose
remained constant throughout the 24-week treatment period. Patients
who developed a loss of glycaemic control during the 24-week treat-
ment period, defined as fasting plasma glucose (FPG) of >13.3 mmol/L
during Weeks 4–12 or FPG of >11.1 mmol/L during Weeks 12–24,
were eligible for open-label rescue medication in addition to the blinded
treatment. Rescue medication could comprise any appropriate glucose-
lowering agent, with the exception of SGLT2 inhibitors.
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Study visits took place during enrolment (Week −6), lead-in
(Weeks −4, −1), randomization (Week 0), double-blind treatment
(Weeks 1, 4, 12, 24) and the follow-up period (Week 27). HbA1c was
recorded at Weeks −6, 0, 4, 12, 24, 27. Body weight and seated SBP
were recorded at Weeks −6, −4, −1, 0, 1, 4, 12, 24, 27. FPG was
recorded at Weeks 0, 4, 12, 24, 27.
2.4 | Endpoints
The primary efficacy outcome was mean change from baseline in HbA1c
at Week 24. Secondary efficacy outcomes comprised mean changes
from baseline in body weight, FPG and seated SBP at Week 24.
Exploratory endpoints included the proportion of patients achiev-
ing HbA1c <7% at 24 weeks, change from baseline in urine albumin:
creatinine ratio (UACR) at Week 24 (all patients and according to albu-
minuria status), change from baseline in fasting serum uric acid at
Week 24 and the number of patients receiving rescue medication
after failing to maintain adequate glycaemic control over 24 weeks.
Safety objectives included adverse events (AEs), serious AEs and AEs
of interest, based on a predefined list of preferred terms from the Medical
Dictionary for Regulatory Activities (MedDRA) (Table S2), including genital
and urinary tract infections, volume depletion, renal impairment/failure,
bone fractures and diabetic ketoacidosis (DKA); mean change from base-
line in heart rate at 24 weeks; mean change in eGFR from baseline to
Week 24 and at the 3-weeks post-treatment follow-up period; the pro-
portion of patients discontinuing study medication because of worsening
renal insufficiency, defined as confirmed eGFR of 30 mL/min/1.73 m2,
over 24 weeks; mean change from baseline in haematocrit at Week 24;
and mean change from baseline in bicarbonate at Week 24.
The proportion of patients who experienced hypoglycaemia
events and the frequency of such events were also evaluated. Major
hypoglycaemia was defined as a symptomatic episode requiring exter-
nal assistance because of severe impairment in consciousness or
behaviour, with a capillary or plasma glucose value <3.0 mmol/L and
prompt recovery after glucose or glucagon administration. Minor
hypoglycaemia was defined as either a symptomatic episode with a
capillary or plasma glucose value <3.5 mmol/L or a capillary or plasma
glucose value <3.5 mmol/L, without symptoms, that does not qualify
as a major episode. Other episodes of hypoglycaemia were defined as
an episode reported by an investigator that did not meet the criteria
for a major or minor episode.
2.5 | Randomization and masking
Eligible patients were assigned a unique randomization code using an
interactive voice response system (IVRS) or interactive web response
system (IWRS). For each randomized patient the IVRS/IWRS provided
the investigator with a unique Kit ID number matching the treatment
arm to which the patient was assigned.
2.6 | Statistical analysis
2.6.1 | Sample size
Assuming a common standard deviation (SD) of 0.9% in the primary
endpoint, 143 patients per treatment group for whom both baseline
and at least 1 post-baseline HbA1c measurements were available
would provide 80% power to detect a predicted treatment difference
of 0.3% in the primary endpoint at a 2-sided significance level of 0.05,
using a 2-sample t-test. Assuming that 5% of randomized patients
failed to qualify for inclusion in the full analysis set because of missing
baseline and/or all post-randomization values for this primary end-
point, a total of 302 randomized patients, 151 per treatment group,
were needed for the study.
2.6.2 | Efficacy analyses
Efficacy analyses were performed on the full analysis set, comprising
all randomized patients who received at least 1 dose of double-blind
study medication and for whom a baseline value and at least 1 post-
baseline efficacy value were available. The primary efficacy analysis,
change from baseline in HbA1c at Week 24, was based on a mixed
effects model with repeated measures (MMRM) using “direct likeli-
hood” which assumed that missing data were missing at random. The
primary analysis included measurements before rescue medication or
discontinuation of the double-blind study medication. The model
included the fixed categorical effects of treatment, week, randomiza-
tion stratification factor (glucose-lowering treatment strata) and
treatment-by-week interaction, as well as the continuous fixed covari-
ate effects of baseline measurement and baseline measurement-by-
week interaction. Point estimates and 95% confidence intervals for
mean change within each treatment group, as well as the difference in
mean change estimates between the dapagliflozin and placebo groups,
were calculated. P values for the differences in estimates at Week
24 between the dapagliflozin and placebo groups were also calculated
and reported at the nominal level. A sequential testing procedure was
employed to accommodate multiple comparisons, whereby tests for
secondary efficacy endpoints (changes from baseline in body weight,
FPG and seated SBP) were performed only if the primary endpoint
comparison, and all previous ordered secondary comparisons, were
significant. Secondary and exploratory endpoints were analysed using
an MMRM, similar to the model used in the primary analysis. Analysis
of covariance (ANCOVA) was used in exploratory analyses for end-
points measured at baseline and at the end of treatment using the last
observation carried forward (LOCF). ANCOVA models contained fixed
categorical effects for randomization stratification factor and treat-
ment, and a fixed covariate effect for baseline measurement.
2.6.3 | Sensitivity analyses
Sensitivity analyses were conducted to assess the robustness of the
primary analysis (Appendix S1).
2.6.4 | Safety analyses
Safety analyses were performed on the safety analysis set, comprising
all patients who received at least 1 dose of double-blind study medi-
cation during the double-blind treatment period. Safety analyses were
performed using descriptive statistics. Comparisons between dapagli-
flozin 10 mg and matching placebo were not made for safety variables
and inferential testing was not performed.
For mean changes from baseline in eGFR, data over 24 weeks
were analysed with missing data assumptions specific to MMRM.
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The study was conducted between June 15, 2015 and November
7, 2017. A total of 321 patients were randomized: 160 to the dapagli-
flozin 10 mg group and 161 to the placebo group (Figure S1). Most
patients completed the study, regardless of discontinuation of double-
blind treatment (156 patients [97.5%] in the dapagliflozin group and
154 patients [95.7%] in the placebo group) and most also completed
the 24-week double-blind treatment period (149 patients [93.1%] in
the dapagliflozin group and 146 patients [90.7%] in the placebo
group). Demographics and baseline characteristics were balanced
between treatment groups (Table 1).
3.2 | Primary endpoint
Dapagliflozin significantly improved HbA1c over 24 weeks, with no
significant change with placebo (Figure 1A). Adjusted mean changes
from baseline (95% CI) at Week 24 were −0.37% (−0.56, −0.18) with
dapagliflozin and −0.03% (−0.22, 0.16) with placebo. The difference
between dapagliflozin and placebo (95% CI) was −0.34% (−0.53,
−0.15); P < 0.001.
3.3 | Secondary endpoints
Dapagliflozin was associated with significant reductions in
body weight over 24 weeks. The adjusted mean change from baseline
(95% CI) at Week 24 was −3.17 kg (−3.76, −2.58) with dapagliflozin
and −1.92 kg (−2.51, −1.34) with placebo (Figure 1B). The difference
between dapagliflozin and placebo (95% CI) was −1.25 kg (−1.90,
−0.59); P < 0.001. The adjusted mean percent change from baseline
(95% CI) in body weight at Week 24 was −3.42% (−4.05, −2.78) with
dapagliflozin and −2.02% (−2.66, −1.38) with placebo. The difference
between dapagliflozin and placebo (95% CI) was −1.43% (−2.15,
−0.69); P < 0.001.
Dapagliflozin significantly improved FPG compared with placebo
over 24 weeks. The adjusted mean change from baseline at
Week 24 (95% CI) was −1.2 mmol/L (−1.8, −0.6) with dapagliflozin
and −0.3 mmol/L (−0.8, 0.3) with placebo (Figure 1C). The difference
between dapagliflozin and placebo (95% CI) was −0.9 mmol/L (−1.5,
−0.4); P = 0.001.
Dapagliflozin significantly reduced seated SBP compared with
placebo over 24 weeks. The adjusted mean change from baseline at
Week 24 (95% CI) was −4.8 mm Hg (−7.7, −1.8) with dapagliflozin
and −1.7 mmHg (−4.6, 1.3) with placebo (Figure 1D). The difference
between dapagliflozin and placebo (95% CI) was −3.1 mm Hg (−6.3,
0.0); P < 0.05.







Age, years, mean (median) 65.3 (66.0) 66.2 (68.0)
Age categories, n (%)
<65 years 64 (40.0) 46 (28.6)
≥65 years 96 (60.0) 115 (71.4)
Sex, n (%)
Male 91 (56.9) 91 (56.5)
Female 69 (43.1) 70 (43.5)
Race, n (%)
White 141 (88.1) 140 (87.0)
Black/African American 11 (6.9) 12 (7.5)
Asian 5 (3.1) 8 (5.0)
American Indian/Alaska native 2 (1.3) 0
Other 1 (0.6) 1 (0.6)
Ethnic group, n (%)
Hispanic or Latino 33 (20.6) 44 (27.3)
Not Hispanic or Latino 127 (79.4) 117 (72.7)
Geographic region, n (%)
North America 64 (40.0) 76 (47.2)
Europe 96 (60.0) 85 (52.8)
Weight, kg, mean (SD) 92.4 (16.8) 88.3 (16.2)
BMI, kg/m2, mean (SD) 32.6 (4.7) 31.6 (5.0)
eGFR, mL/min/173 m2,
mean (SD)
53.3 (8.7) 53.6 (10.6)
UACR mg/g, median (range) 23.5 (2.7–5852.0) 29.0 (3.8-8474.0)
Duration since T2D diagnosis,
mean, years (SD)
14.3 (8.1) 14.5 (8.3)
HbA1c, %, mean (SD) 8.33 (1.08) 8.03 (1.08)
HbA1c by category, n (%)
<8 61 (38.1) 93 (57.8)
≥8 to <9 56 (35.0) 40 (24.8)
≥9 to <10 29 (18.1) 19 (11.8)
≥10 14 (8.8) 9 (5.6)
FPG, mmol/L, mean (SD) 10.1 (3.7) 9.6 (3.0)
SBPa, mm Hg, mean (SD) 135.7 (14.6) 135.0 (15.6)
Glucose-lowering treatment,
n (%)
Insulin 80 (50.0) 80 (49.7)
Metformin 111 (69.4) 103 (64.0)
Sulphonylurea 64 (40.0) 67 (41.6)
Antihypertensive treatment,
n (%)
ACE inhibitor/ARB 137 (85.6) 132 (82.0)
Diuretics 67 (41.9) 68 (42.2)
Beta blockers 59 (36.9) 77 (47.8)
Other antihypertensive 21 (13.1) 20 (12.4)
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II
receptor blocker; BMI, body mass index; eGFR, estimated glomerular
filtration rate; FPG, fasting plasma glucose; SBP, systolic blood pressure;
SD, standard deviation; T2D, type 2 diabetes; UACR, urine
albumin-to-creatinine ratio.
a SBP data are based on the full analysis set (n = 158 for dapagliflozin,
n = 161 for placebo); all other data are based on all randomized patients.
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3.4 | Exploratory endpoints
The adjusted proportion of patients achieving HbA1c <7% (95% CI) at
24 weeks (LOCF) was similar between the dapagliflozin and placebo
groups (12.1% [7.4, 19.1] vs 8.3% [4.7, 14.2], respectively; P = 0.209).
Dapagliflozin did not reduce mean percent changes from baseline
in UACR at Week 24 in the overall population (difference vs placebo
[95% CI], 8.0% [−14.4, 36.3]; P = 0.513) (Figure S2A). However, in
patients with baseline UACR ≥30 mg/g, mean percent reductions
from baseline in UACR were observed with dapagliflozin relative to
placebo at Week 4 (difference [95% CI], −30.7% [−47.3, −8.9];
P = 0.009) and at Week 12 (difference [95% CI], −41.7% [−57.1,
−21.0]; P < 0.001). Although the mean percent reductions from base-
line in UACR were maintained from Week 12 to Week 24 with dapa-
gliflozin, the difference vs placebo at Week 24 was not significant
(−14.0% [−42.3, 28.0]; P = 0.454) (Figure S2B), because of a decrease
in UACR from Week 12 to Week 24 in the placebo group.
Dapagliflozin was associated with significant reductions in fasting
serum uric acid compared with placebo at Week 24 (LOCF; adjusted
mean changes from baseline [95% CI], −11.9 μmol/L [−32.1, 8.3] vs
13.0 μmol/L [−6.8, 32.8]; difference [95% CI], −24.9 [−40.7, −9.0];
P = 0.002).
The number of patients receiving rescue medication after failing
to maintain adequate glycaemic control during the 24-week treatment
period was similar between the dapagliflozin and placebo groups
(8 [5.0%] vs 10 [6.2%], respectively; difference [95% CI], −1.2 [−6.2,
3.9]; P = 0.809).
3.5 | Safety outcomes
Dapagliflozin was well-tolerated and AEs were balanced between
treatment arms, with numerically fewer AEs (41.9% vs 47.8%) and
serious AEs (5.6% vs 8.7%) reported with dapagliflozin than with pla-
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Difference vs placebo: -1.25 kg (95% CI -1.90, -0.59); P < 0.001
(B)
FIGURE 1 Adjusted mean change from baseline (95% CI) in A, HbA1c; B, body weight; C, FPG; and D, Seated SBP, over 24 weeks (full analysis
set). A, Mean baseline HbA1c (SD), 8.35% (1.06) with dapagliflozin and 8.03% (1.09) with placebo; adjusted mean change from baseline in HbA1c
at Week 24 (95% CI), −0.37% (−0.56, −0.18) with dapagliflozin and −0.03% (−0.22, 0.16) with placebo. B, Mean baseline body weight (SD), 92.51
(16.73) kg with dapagliflozin and 88.30 (16.23) kg with placebo; adjusted mean change from baseline at Week 24 (95% CI), −3.17 kg (−3.76,
−2.58) with dapagliflozin and −1.92 kg (−2.51, −1.34) with placebo. C, Mean baseline FPG (SD), 10.2 (3.7) mmol/L with dapagliflozin and 9.6 (3.0)
mmol/L with placebo; adjusted mean change from baseline at Week 24 (95% CI), −1.2 mmol/L (−1.8, −0.6) and −0.3 mmol/L (−0.8, 0.3) with
placebo. (D) Mean baseline seated SBP (SD), 135.7 (14.6) mm Hg with dapagliflozin and 135.0 (15.6) mm Hg with placebo; adjusted mean change
from baseline at Week 24 (95% CI), −4.8 mm Hg (−7.7, −1.8) and −1.7 mm Hg (−4.6, 1.3) with placebo. CI, confidence interval; FPG, fasting
plasma glucose; SBP, systolic blood pressure; SD, standard deviation
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discontinuation of study medication was also balanced between the
dapagliflozin and placebo groups (1.9% in both). One patient in the
dapagliflozin group had an eGFR value of 30.3 mL/min/1.73 m2 that
was registered by the investigator as an AE; however, eGFR returned
to baseline following discontinuation of study medication. Patients in
the dapagliflozin and placebo groups had similar percentages of uri-
nary tract infections (2.5% vs 3.7%) and genital infections (1.9% vs
1.2%) (Table 2).
Few AEs of hypotension/dehydration/hypovolaemia (1.9% vs
0.0%) or renal impairment/failure (0.6% vs 1.2%) were reported. No
AEs of bone fractures, amputations or DKA were reported and no
patients had elevated liver enzymes or experienced liver-related AEs.
There were no meaningful changes in seated heart rate at Week
24 (mean changes from baseline [SD], −0.2 [8.9] bpm with dapagliflo-
zin [baseline value, 73.1 bpm] vs −0.2 [8.8] bpm with placebo [baseline
value, 73.7 bpm]).
The proportion of patients with hypoglycaemia was balanced
between the dapagliflozin and placebo groups (12.5% vs 13.7%,
respectively), with the majority of these patients receiving insulin
(8.8% vs 11.8%, respectively) (Table 3). No patients discontinued
study medication because of hypoglycaemia and no episodes of major
hypoglycaemia were reported.
Decreases from baseline in eGFR were larger with dapagliflozin
compared with placebo after 4 weeks (difference vs placebo [95% CI],
−4.90 mL/min/1.73 m2 [−6.73, −3.07]), after 12 weeks (difference vs
placebo [95% CI], −4.75 mL/min/1.73 m2 [−6.98, −2.52]) and after
24 weeks (difference vs placebo [95% CI], −2.49 mL/min/1.73 m2
[−4.96, −0.02]) (Figure 2). With the inclusion of 3 weeks of off-
treatment data, eGFR returned to baseline at Week 27 (difference vs
placebo [95% CI], 0.61 mL/min/1.73 m2 [−1.59, 2.81]) (Figure 2). One
patient in the dapagliflozin group met a pre-defined safety
objective of worsening renal insufficiency, defined as a confirmed eGFR
level < 30 mL/min/1.73 m2, but eGFR returned to baseline following
study drug interruption. This episode was not reported as an AE.
Mean changes from baseline in haematocrit (SD) at Week 24 were
2.5% (2.9) and 0.3% (3.1) with dapagliflozin and placebo, respectively,
and mean changes from baseline in bicarbonate (SD) at Week
24 were −0.40 (2.52) mmol/L and 0.43 (2.51) mmol/L, respectively.
4 | DISCUSSION
In this study, dapagliflozin significantly improved glycaemic control,
body weight and SBP over 24 weeks in patients with T2D and CKD
stage 3A, with a safety profile consistent with established parameters
for this treatment.
Placebo-corrected reductions in HbA1c of −0.34% were reported
at Week 24, which, while lower than those in patients with normal
renal function,20–22 were almost identical to a post hoc analysis of the
Kohan et al. study in patients with T2D and CKD stage 3A18 and with
a pooled analysis of 11 randomized controlled trials by Petrykiv
et al.23 The extent of HbA1c lowering in the current study was also
similar to that observed with other SGLT2 inhibitors in patients with
CKD stage 3.24,25
The benefits concerning body weight and SBP that were indepen-
dent of renal function in this study are in line with previous reports of
benefits with the use of dapagliflozin.18,23 Petrykiv et al. reported
reductions in body weight and SBP with dapagliflozin 10 mg regard-
less of baseline renal function, which were accompanied by increases
in haematocrit and decreases in UACR, eGFR, bicarbonate and uric
acid.23 It is noteworthy that the reductions in SBP seen in our study
with use of dapagliflozin were not accompanied by changes in heart
rate. Previous studies indicate that higher resting heart rate and lower
heart rate variability are both risk factors for end-stage renal disease
(ESRD) and CKD-related hospitalizations.26 Glucose-lowering treat-
ments that reduce body weight and SBP without affecting heart rate
may be particularly valuable in this population.
SGLT2 treatment is associated with a transient drop in eGFR that
is reversible after treatment discontinuation.11,25,27 Findings from the
current trial were consistent with findings concerning patients with
normal or near-normal renal function, for whom dapagliflozin treat-
ment is associated with reversible decreases in eGFR and long-term
eGFR stabilization.11 Interestingly, in the present study, there was a
trend to recovery of eGFR towards baseline values at Week 24, similar
to what is seen in patients with normal renal function. Dapagliflozin
was also associated with a decrease in UACR over 24 weeks in
patients with baseline UACR ≥30 mg/g and with a significant differ-
ence relative to placebo at Weeks 4 and 12. However, improvements
in the placebo arm at Week 24 resulted in a non-significant difference
in UACR between the dapagliflozin and placebo groups at this specific
time-point. This decrease in UACR is consistent with previous obser-
vations concerning dapagliflozin.28
AEs were generally balanced between treatment groups in this
study. The frequency of hypoglycaemia, urinary tract infections and
genital infections was similar between treatment groups and no DKA






Any AE 67 (41.9) 77 (47.8)
Any related AE 17 (10.6) 10 (6.2)
Any AE leading to discontinuation 3 (1.9) 3 (1.9)
Death 0 0
Serious AEs
Any serious AE 9 (5.6) 14 (8.7)
Any related serious AE 1 (0.6) 0
Any serious AE leading to
discontinuation
2 (1.3) 2 (1.2)
AEs of interest
Genital infection 3 (1.9) 2 (1.2)




Renal impairment/failure 1 (0.6) 2 (1.2)
Bone fractures 0 0
DKA 0 0
Non-serious AEs were included up to the last day of double-blind treat-
ment plus 4 days. Serious AEs were included up to the last day of
double-blind treatment plus 30 days. Includes data after rescue. Abbrevia-
tions: AE, adverse event; DKA, diabetic ketoacidosis.
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TABLE 3 Summary of hypoglycaemia events (safety analysis set)
Dapagliflozin 10 mg (N = 160) Placebo (N = 161)
Patients, n (%) Events, n Patients, n (%) Events, n
Total 20 (12.5) 44 22 (13.7) 62
Major 0 0 0 0
Minor 12 (7.5) 34 16 (9.9) 53
Other 8 (5.0) 10 6 (3.7) 9
Insulin-based total 14 (8.8) 27 19 (11.8) 53
Major 0 0 0 0
Minor 9 (5.6) 21 13 (8.1) 44
Other 5 (3.1) 6 6 (3.7) 9
Metformin-based total 6 (3.8) 17 3 (1.9) 9
Major 0 0 0 0
Minor 3 (1.9) 13 3 (1.9) 9
Other 3 (1.9) 4 0 0
Sulphonylurea-based total 0 0 0 0
Thiazolidinediones-based total 0 0 0 0
Other total 0 0 0 0
































































Dapagliflozin 10 mg (N=160)
Dapagliflozin
Placebo
155 148 150 150













Baseline mean (SD) 53.48 (8.76) 53.68 (10.67)
Difference in adjusted mean change from 







FIGURE 2 Adjusted mean change from baseline in eGFR (95% CI) during 24-week treatment period and 3-week follow-up period (safety analysis
set). †Data analysed with missing data assumptions specific to the repeated measures model, with missing data considered to be missing at
random. ‡Data analysed separately using an extension of the analysis model to include Week 27, enabling the pattern in missing data to change
with the inclusion of post-treatment follow-up. CI, confidence interval; eGFR, estimated glomerular filtration rate; SD, standard deviation
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events, elevated liver enzymes or liver-related AEs were reported. In
addition, no AEs of bone fractures or amputations were reported dur-
ing the study, consistent with previous studies.29,30
Limitations to this study include the timeframe, which was too
short to assess long-term effects of dapagliflozin. Furthermore, the
vast majority of patients were Caucasian (>87%), restricting generaliz-
ability of the results. Another potential limitation is that patients with
recent CV events and a rapid decline in eGFR during the pre-
randomization visit were excluded, as were patients receiving certain
glucose-lowering medications (ie, GLP-1 receptor agonists and rapid/
short-acting insulin).
As expected, glycaemic efficacy with dapagliflozin was lower than
that reported in patients with normal renal function, consistent with
previous studies on SGLT2 inhibitors18,24,25 and in line with their
mode of action, which is dependent on GFR and, subsequently, the fil-
tered glucose load.17 However, the clinical value of dapagliflozin was
demonstrated within this population, including significant improve-
ments in HbA1c and FPG, in addition to reductions in body weight,
SBP, serum uric acid and UACR.
The long-term renal benefits of dapagliflozin in CKD are currently
being explored in an ongoing renal outcomes study (NCT03036150;
DAPA-CKD). In addition, 2 CV outcome trials are currently in pro-
gress; these involve patients with T2D and either established CV dis-
ease or multiple CV risk factors (NCT01730534; DECLARE-TIMI
58)31 or chronic heart failure (NCT03036124; DAPA-HF). The efficacy
and safety of dapagliflozin in patients with T2D, albuminuria and mod-
erate renal impairment is also being investigated in an ongoing study
(NCT02547935).
In conclusion, significant improvements in HbA1c, body weight
and SBP over 24 weeks in patients with T2D and stage 3A CKD were
demonstrated with use of dapagliflozin, with no increase in AEs or
serious AEs. The findings of this study support a positive benefit/risk
profile of dapagliflozin in patients with T2D and CKD stage 3A.
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